Long-Term Effects and Clinical Burden Associated with Immune Checkpoint Inhibitor Toxicities in Cancer Patients

Overview

This study evaluates the long-term effects and clinical burden of immune-related adverse events (irAEs) in cancer patients treated with immune checkpoint inhibitors (ICIs). Key findings indicate that 61% of patients experienced chronic toxicity, and management of irAEs significantly increased clinical workload.

Background

Immune checkpoint inhibitors are crucial in cancer therapy, yet over 50% of treated patients experience irAEs. Understanding the chronicity and healthcare implications of these toxicities is essential for optimizing patient care.

Data Highlights

No numerical data table available.

Key Findings

• 61% of patients with irAEs had chronic toxicity lasting over 12 weeks.
• 43% of irAEs required corticosteroid treatment, with 49% undergoing prolonged therapy beyond 12 weeks.
• Management of irAEs necessitated an average of 5.3 contacts with a medical oncologist per irAE.
• Chronic irAEs often lead to increased risk of steroid-related adverse events.
• Endocrine, dermatological, and nervous system irAEs are particularly prone to chronicity.

Clinical Implications

Healthcare providers should be aware of the potential for chronic irAEs in patients receiving ICIs.

Conclusion

The findings highlight the significant long-term effects and clinical burden of irAEs in cancer patients treated with ICIs.

Related Resources & Content

1. The ASCO Post, 2018 -- Immunotherapy-Related Toxicities May Be More Common Than Originally Reported
2. The ASCO Post, 2022 -- Incidence of Major Adverse Cardiac Events in Patients Receiving Immune Checkpoint Inhibitors
3. The ASCO Post, 2018 -- Both Patients and Clinicians Face Challenges in Recognizing and Reporting Immune-Related Adverse Events
4. NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024 - PubMed
5. Multi-institutional analysis of incidence and risks for late-onset immune toxicity in breast cancer | npj Breast Cancer
6. The ASCO Post — Physician-Patient Partnership Is Key to Recognizing and Managing Side Effects of Immune Checkpoint Inhibitors
7. NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024 - PubMed
8. Multi-institutional analysis of incidence and risks for late-onset immune toxicity in breast cancer | npj Breast Cancer
9. Temporal trends, sociodemographic factors, and healthcare utilization of immune-related adverse events in hospitalized cancer patients: A national analysis, 2016-2020. | Journal of Clinical Oncology